Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chien-Yu, Wei, Sheng-Huan, Chen, Yi-Lin, Lee, Chung-Ta, Wu, Shang-Yin, Ho, Chung-Liang, Pavlick, Dean C., Su, Po-Lan, Lin, Chien-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404301/
https://www.ncbi.nlm.nih.gov/pubmed/36033470
http://dx.doi.org/10.3389/fonc.2022.919123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404301/
https://www.ncbi.nlm.nih.gov/pubmed/36033470
http://dx.doi.org/10.3389/fonc.2022.919123

Ejemplares similares